Withdrawn
A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin SCA-136 in Japanese Subjects With Acute Exacerbation of Schizophrenia
Led by Wyeth is now a wholly owned subsidiary of Pfizer · Updated on 2013-01-29
N/A
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone.
CONDITIONS
Brief Title
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- Male and female subjects between >=20 and =<65 years of age
- Current diagnosis and DSM-IV-TR diagnosis of schizophrenia type (295.10, 295.30 and 295.90)
- Total PANSS score >=70 and =< 120
Exclusion Criteria:
- Subjects who are hospitalized against their will
- Current Axis I primary psychiatric diagnosis other than schizophrenia
- A score of 3 on CDSS question 8 which pertains to suicide
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here